The prevalence of non-alcoholic fatty liver disease (NAFLD) has risen and in particular patients with the inflammatory subform NASH have an increased risk of developing hepatocellular carcinoma (HCC). Due to the overall mostly poor prognosis of HCC the development of new therapeutic approaches is of high clinical relevance. This project investigates the therapeutic value of the targeted blockade of IL-1R1 in liver cells in liver cancer development in a novel NASH-HCC mouse model using transgenic mice, cell culture systems and a patient cohort with NASH-HCC, where both relevant clinical data and liver tumour tissue are available for the generation and analysis of ex vivo organoid cultures.

Here you can get further information.